Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 38Neoplasms 22Motor Activity 12Colorectal Neoplasms 9Lung Neoplasms 8Stomach Neoplasms 7Pain, Postoperative 7Fatigue 7Anxiety Disorders 6Pain 5Carcinoma, Hepatocellular 5Rectal Neoplasms 4Polycystic Ovary Syndrome 4Leukemia, Myeloid, Acute 4Depression 4Colonic Neoplasms 4Thyroid Neoplasms 3Stomatitis 3Squamous Cell Carcinoma of Head and Neck 3Sleep Initiation and Maintenance Disorders 3Prostatic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Ovarian Neoplasms 3Malnutrition 3Liver Neoplasms 3Head and Neck Neoplasms 3Agnosia 3Vomiting 2Uterine Cervical Neoplasms 2Urinary Incontinence 2

Interventions

Sodium Bicarbonate 1Saline Solution 1Population Groups 1Intubation 1Health Information Exchange 1Fluoridation 1Fentanyl 1Electrocardiography 1Control Groups 1Bupivacaine 1Atropine 1Anesthesia, General 1Anesthesia, Epidural 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Arrhythmias, Cardiac × Control Groups × Clear all
NCT06092606 2023-10-23

A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients

Monyan Pharmaceutical (Shanghai) Co., Ltd.

Phase 2 Unknown
90 enrolled

Arrhythmias, Cardiac, Heart Failure, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡